A Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Healthy Subjects, and Subjects With Mild to Moderate Atopic Dermatitis
This is a Phase I/IIa Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Efficacy of AR100DP1 in Health Subjects, and Subjects with Mild to Moderate Atopic Dermatitis.
100 Clinical Results associated with Arjil Pharmaceuticals LLC
0 Patents (Medical) associated with Arjil Pharmaceuticals LLC
100 Deals associated with Arjil Pharmaceuticals LLC
100 Translational Medicine associated with Arjil Pharmaceuticals LLC